Nanoceria ameliorates doxorubicin induced cardiotoxicity: Possible mitigation via reduction of oxidative stress and inflammation

Journal of Trace Elements in Medicine and Biology

Volumn 47, Issue , 2018, Pages 53-62

  Sangomla, Swetha ^a   Saifi, Mohd Aslam ^a   Khurana, Amit ^a   Godugu, Chandraiah ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cardiotoxicity; Doxorubicin; Inflammation; Nanoceria; Oxidative stress

Indexed keywords

CATALASE; CERIUM OXIDE NANOPARTICLE; CREATINE KINASE MB; DOXORUBICIN; GLUTATHIONE; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MALONALDEHYDE; NANOCERIA; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIOXIDANT; CARDIOTONIC AGENT; CERIC OXIDE; CERIUM; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ATOMIC EMISSION SPECTROMETRY; BODY WEIGHT; BODY WEIGHT LOSS; CARDIOTOXICITY; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART INJURY; HEART TISSUE; HEART WEIGHT; HISTOPATHOLOGY; HYDRODYNAMICS; INFLAMMATION; INFRARED RADIATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BLOOD; CARDIAC MUSCLE; CHEMISTRY; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART; INFRARED SPECTROSCOPY; MALE; METABOLISM; ORGAN SIZE; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; CARDIOTONIC AGENTS; CARDIOTOXICITY; CERIUM; CYTOKINES; DOXORUBICIN; ELECTROCARDIOGRAPHY; HEART; INFLAMMATION; L-LACTATE DEHYDROGENASE; MALE; MICE; MYOCARDIUM; ORGAN SIZE; OXIDATIVE STRESS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 85043324233     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2018.01.016     Document Type: Article

References (42)

1. Xu, M.F., Tang, P.L., Qian, Z.M., Ashraf, M., Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 68:8 (2001), 889–901.
2. Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., Geršl, V., Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 61:1 (2009), 154–171.
3. Horenstein, M.S., Vander Heide, R.S., L'Ecuyer, T.J., Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol. Genet. Metab. 71:1 (2000), 436–444.
4. Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., Schlattner, U., New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J. Mol. Cell. Cardiol. 41:3 (2006), 389–405.
5. Liou, G.Y., Storz, P., Reactive oxygen species in cancer. Free Radic. Res. 44:5 (2010), 479–496.
6. Pop-Busui, R., Sima, A., Stevens, M., Diabetic neuropathy and oxidative stress. Diabetes Metab. Res. Rev. 22:4 (2006), 257–273.
7. Bonomini, F., Rodella, L.F., Rezzani, R., Metabolic syndrome, aging and involvement of oxidative stress. Aging and disease, 6(2), 2015, 109.
8. Kaneto, H., Katakami, N., Matsuhisa, M., Matsuoka, T.-a., Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators ofinflammation, 2010, 2010.
9. Seifert, C.F., Nesser, M.E., Thompson, D.F., Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann. Pharmacother. 28:9 (1994), 1063–1072.
10. Savasan, S., Ozdemir, O., Buck, S., Ravindranath, Y., Differential effect of Dexrazoxane on the in vitro cytotoxicity of topoisomerase-II inhibitors by cell type in childhood leukemias. Leukemia, 15(3), 2001, 489.
11. Granados-Principal, S., El-azem, N., Pamplona, R., Ramirez-Tortosa, C., Pulido-Moran, M., Vera-Ramirez, L., Quiles, J.L., Sanchez-Rovira, P., Naudí, A., Portero-Otin, M., Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer. Biochem. Pharmacol. 90:1 (2014), 25–33.
12. Zhang, X.Y., Li, W.G., Wu, Y.J., Gao, M.T., Amelioration of doxorubicin‐induced myocardial oxidative stress and immunosuppression by grape seed proanthocyanidins in tumour‐bearing mice. J. Pharm. Pharmacol. 57:8 (2005), 1043–1051.
13. 2O system. J. Electrochem. Soc. 149:12 (2002), C623–C630.
14. Celardo, I., Traversa, E., Ghibelli, L., Cerium oxide nanoparticles: a promise for applications in therapy. J. Exp. Ther. Oncol. 9:1 (2011), 47–51.
15. Korsvik, C., Patil, S., Seal, S., Self, W.T., Superoxide dismutase mimetic properties exhibited by vacancy engineered ceria nanoparticles. Chem. Commun. 10 (2007), 1056–1058.
16. Pirmohamed, T., Dowding, J.M., Singh, S., Wasserman, B., Heckert, E., Karakoti, A.S., King, J.E., Seal, S., Self, W.T., Nanoceria exhibit redox state-dependent catalase mimetic activity. Chem. Commun. 46:16 (2010), 2736–2738.
17. Dowding, J.M., Dosani, T., Kumar, A., Seal, S., Self, W.T., Cerium oxide nanoparticles scavenge nitric oxide radical (̇ NO). Chem. Commun. 48:40 (2012), 4896–4898.
18. Asati, A., Santra, S., Kaittanis, C., Perez, J.M., Surface-charge-dependent cell localization and cytotoxicity of cerium oxide nanoparticles. ACS nano 4:9 (2010), 5321–5331.
19. Tarnuzzer, R.W., Colon, J., Patil, S., Seal, S., Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano Lett. 5:12 (2005), 2573–2577.
20. Giri, S., Karakoti, A., Graham, R.P., Maguire, J.L., Reilly, C.M., Seal, S., Rattan, R., Shridhar, V., Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLoS One, 8(1), 2013, e54578.
21. Kumar, G.S., Kulkarni, A., Khurana, A., Kaur, J., Tikoo, K., Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy. Chem. Biol. Interact. 223 (2014), 125–133.
22. Moron, M.S., Depierre, J.W., Mannervik, B., Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim. Biophys. Acta (BBA) 582:1 (1979), 67–78 (-General Subjects).
23. Aebi, H., [13] catalase in vitro. Methods Enzymol. 105 (1984), 121–126.
24. Hirst, S.M., Karakoti, A., Singh, S., Self, W., Tyler, R., Seal, S., Reilly, C.M., Bio‐distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. Environ. Toxicol. 28:2 (2013), 107–118.
25. Granados-Principal, S., Quiles, J.L., Ramirez-Tortosa, C.L., Sanchez-Rovira, P., Ramirez-Tortosa, M., New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem. Toxicol. 48:6 (2010), 1425–1438.
26. Hoye, A.T., Davoren, J.E., Wipf, P., Fink, M.P., Kagan, V.E., Targeting mitochondria. Acc. Chem. Res. 41:1 (2008), 87–97.
27. Goormaghtigh, E., Chatelain, P., Caspers, J., Ruysschaert, J.M., Evidence of a complex between adriamycin derivatives and cardiolipin: possible role in cardiotoxicity. Biochem. Pharmacol. 29:21 (1980), 3003–3010.
28. Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R., Ruysschaert, J.-M., Structure of the adriamycin-cardiolipin complex: role in mitochondrial toxicity. Biophys. Chem. 35:2 (1990), 247–257.
29. Berthiaume, J., Wallace, K., Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 23:1 (2007), 15–25.
30. Hulbert, A., Pamplona, R., Buffenstein, R., Buttemer, W., Life and death: metabolic rate, membrane composition, and life span of animals. Physiol. Rev. 87:4 (2007), 1175–1213.
31. Tamura, M., Matsui, H., Kaneko, T., Hyodo, I., Alcohol is an oxidative stressor for gastric epithelial cells: detection of superoxide in living cells. J. Clin. Biochem. Nutr. 53:2 (2013), 75–80.
32. Singal, P., Li, T., Kumar, D., Danelisen, I., Iliskovic, N., Adriamycin-induced heart failure: mechanisms and modulation. Mol. Cell. Biochem. 207:1-2 (2000), 77–86.
33. Ascensao, A., Magalhaes, J., Soares, J., Ferreira, R., Neuparth, M., Marques, F., Oliveira, J., Duarte, J., Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int. J. Cardiol. 100:3 (2005), 451–460.
34. Zhang, C., Feng, Y., Qu, S., Wei, X., Zhu, H., Luo, Q., Liu, M., Chen, G., Xiao, X., Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc. Res. 90:3 (2011), 538–545.
35. Rao, P.R., Viswanath, R.K., Cardioprotective activity of silymarin in ischemia-reperfusion-induced myocardial infarction in albino rats. Exp. Clin. Cardiol., 12(4), 2007, 179.
36. Jensen, R., Acton, E., Peters, J., Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. J. Cardiovasc. Pharmacol., 6(1), 1984, l201.
37. Danesi, R., del Tacca, M., Bernardini, C., Penco, S., Exogenous doxorubicinol induces cardiotoxic effects in rats. Eur. J. Cancer Clin. Oncol. 23:7 (1987), 907–913.
38. Roberts, R.A., Smith, R.A., Safe, S., Szabo, C., Tjalkens, R.B., Robertson, F.M., Toxicological and pathophysiological roles of reactive oxygen and nitrogen species. Toxicology 276:2 (2010), 85–94.
39. Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T., Mazur, M., Telser, J., Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39:1 (2007), 44–84.
40. Alili, L., Sack, M., von Montfort, C., Giri, S., Das, S., Carroll, K.S., Zanger, K., Seal, S., Brenneisen, P., Downregulation of tumor growth and invasion by redox-active nanoparticles. Antioxid. Redox Signaling 19:8 (2013), 765–778.
41. Gonzalez-Flores, D., De Nicola, M., Bruni, E., Caputo, F., Rodríguez, A.B., Pariente, J.A., Ghibelli, L., Nanoceria protects from alterations in oxidative metabolism and calcium overloads induced by TNFí and cycloheximide in U937 cells: pharmacological potential of nanoparticles. Mol. Cell. Biochem. 397:1-2 (2014), 245–253.
42. Cheng, G., Guo, W., Han, L., Chen, E., Kong, L., Wang, L., Ai, W., Song, N., Li, H., Chen, H., Cerium oxide nanoparticles induce cytotoxicity in human hepatoma SMMC-7721 cells via oxidative stress and the activation of MAPK signaling pathways. Toxicol. In Vitro 27:3 (2013), 1082–1088.